Suggested remit: To appraise the clinical and cost effectiveness of treatments for non-small-cell lung cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commencing
Process Pathways Pilot
ID number 6234

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group Bristol Technology Assessment Group, University of Bristol

Stakeholders

Others Department of Health and Social Care
  NHS England
Patient carer groups ALK Positive UK
  EGFR Positive UK
  Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  British Thoracic Oncology Group
  British Thoracic Society
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Pathway companies:
  AbbVie
  Amarox (erlotinib) – confidentiality agreement not signed, not participating
  AstraZeneca (durvalumab, osimertinib)
  Boehringer Ingelheim (afatinib) – confidentiality agreement not signed, not participating
  Cipla EU (gefitinib) – confidentiality agreement not signed, not participating
  Daiichi Sankyo (trastuzumab deruxtecan)
  GlaxoSmithKline
  Johnson & Johnson Innovative Medicine (amivantamab)
  Merck (tepotinib)
  Novartis (ceritinib, dabrafenib, trametinib)
  Pfizer (crizotinib, dacomitinib, lorlatinib) – confidentiality agreement not signed, not participating
  Regeneron (cemiplimab) – confidentiality agreement not signed, not participating
  Roche (alectinib)
  Takeda (brigatinib)
  Comparator companies:
  Amgen (sotorasib)
  Aspire Pharma (pemetrexed) – confidentiality agreement not signed, not participating
  Bayer (laroctrectinib)
  Boehringer Ingelheim (nintedanib) – confidentiality agreement not signed, not participating
  Bristol Myers Squibb (nivolumab, paclitaxel)
  Celltrion Healthcare UK (bevacizumab) – confidentiality agreement not signed, not participating
  Dr Reddy’s Laboratories (pemetrexed) – confidentiality agreement not signed, not participating
  Eli Lilly (selpercatinib, pemetrexed)
  Genus Pharmaceuticals (pemetrexed) – confidentiality agreement not signed, not participating
  Hospira UK (cisplatin, carboplatin, oxaliplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed) – confidentiality agreement not signed, not participating
  Inceptua (paclitaxel) – confidentiality agreement not signed, not participating
  Medac (oxaliplatin, vinorelbine) – confidentiality agreement not signed, not participating
  Merck Sharp & Dohme UK (pembrolizumab)
  Mylan (pemetrexed) – confidentiality agreement not signed, not participating
  Organon Pharma (bevacizumab) – confidentiality agreement not signed, not participating
  Pfizer (pemetrexed, bevacizumab) – confidentiality agreement not signed, not participating
  Pierre Fabre (vinorelbine) – confidentiality agreement not signed, not participating
  Roche (atezolizumab, bevacizumab entrectinib)
  Sandoz (cisplatin, pemetrexed) – confidentiality agreement not signed, not participating
  Sanofi
  Seacross Pharmaceuticals (oxaliplatin, docetaxel, paclitaxel) – confidentiality agreement not signed, not participating
  Takeda (mobocertinib)
  Thornton and Ross (bevacizumab) – confidentiality agreement not signed, not participating
  Zentiva (bevacizumab) – confidentiality agreement not signed, not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
15 February 2024 Following feedback on the pilot projects for the pathway approach, NICE is currently assessing what principles and lessons of the pathway pilots it will incorporate into the Single Technology Appraisal (STA) process. Considering the re-focus to align with ongoing strategic ambitions and there being no live topics in the NSCLC pilot, the committee meeting scheduled for 27 March 2024 will not be going ahead. Production of the NSCLC model continues, and the model and a model report will be published later in 2024 on this webpage. The process statement will remain on this webpage, for transparency about the intended pathway approach but will no longer be used.
03 October 2023 Stakeholder workshop
01 August 2023 Invitation to participate
01 August 2023 Any companies with a medicine that meets the eligibility and selection criteria for technology appraisal guidance (see sections 4.1.4 and 6.2.1 of the manual) can request to become a NSCLC pathway company stakeholder. Companies with medicines which are expected to get appropriate regulatory approval beyond 24 months are also eligible to request to become a pathway stakeholder. For more information please email TAteam6@nice.org.uk.
21 July 2023 The scope of the first iteration of the NSCLC pathway will focus on development of the evidence synthesis of currently available data and the core model development. Opportunities for stakeholder development will be shared in due course.
24 April 2023 (12:30) Scoping workshop
27 February 2023 - 27 March 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6234
27 February 2023 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual